A radiation-controlled molecular switch for use in gene therapy of cancer.
AuthorsScott, S D
Hendry, Jolyon H
Lashford, Linda S
Embleton, M J
Hunter, Robin D
Margison, Geoffrey P
AffiliationCancer Research Campaign Section of Genome Damage and Repair, Paterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.
MetadataShow full item record
AbstractIonising radiation induces the expression of a number of radiation-responsive genes and there is current interest in exploiting this to regulate the expression of exogenous therapeutic genes in gene therapy strategies for cancer. However, the radiation-responsive promoters used in these approaches are often associated with low and transient levels of therapeutic gene expression. We describe here a novel radiation-triggered molecular switching device based on promoter elements from the radiation-responsive Egr-1 gene and the cre-LoxP site-specific recombination system of the P1 bacteriophage. Using this system, a single, minimally toxic dose of radiation induced cre-mediated excision of a lox-P flanked stop cassette in a silenced expression vector and this resulted in amplified levels of CMV-promoter-driven expression of the exogenous tumour-sensitising gene, HSV-tk. This strategy could be used in combination with targeted delivery and tumour-specific promoters to elicit the tumour-targeted and prolonged expression of a variety of tumour-sensitising genes and provide an unprecedented level of control and tumour selectivity.
CitationA radiation-controlled molecular switch for use in gene therapy of cancer. 2000, 7 (13):1121-5 Gene Ther.
- Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
- Authors: Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD
- Issue date: 2006 Feb
- Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
- Authors: Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC
- Issue date: 2002
- TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
- Authors: Pasanen T, Hakkarainen T, Timonen P, Parkkinen J, Tenhunen A, Loimas S, Wahlfors J
- Issue date: 2003 Oct
- Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK.
- Authors: Hodish I, Tal R, Shaish A, Varda-Bloom N, Greenberger S, Rauchwerger A, Breitbart E, Bangio L, Ben-Shushan D, Pfeffer R, Feder B, Waitsman A, Barshack I, Goldberg I, Mazaki-Tovi S, Peled M, Harats D
- Issue date: 2009 Mar
- Development of synthetic promoters for radiation-mediated gene therapy.
- Authors: Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP
- Issue date: 2000 Mar